Norwegian Colorectal Cancer Registry

The Norwegian Colorectal Cancer Registry contains data on rectal cancer dating back to 1993, and data on colon cancer dating back to 2007.
Last updated: 8/31/2022

Summary from the annual report 2021

This annual report includes all patients with colon and rectal cancer in all stages for the period 2012–2021. The reference group (NGICG-CR) for the Norwegian colorectal cancer registry has defined quality indicators relevant for this group of patients accompanied by target levels. See figure 1.1 and 1.3 for an overview of national quality indicators and results. The results for the quality indicators are presented in chapter 3.

Colon cancer

The quality indicators for colon cancer show that seven indicators reach the target for optimal achievement and one indicator show a moderate level of achievement. The reporting rate for clinical reports are 76.7 % for diagnostic work-up and 85.2 % for surgery reports. Estimated relative survival five years after surgery is 89.6 % (stage I–III only), and for all stages combined, the 5-year relative survival is 71.9 % (irrespective of surgery and or other treatment). The postoperative mortality rate up to 100 days after surgery is 2.0 %. The proportion of patients who do not develop metastasis five years after surgery is 86.0 % and has remained stable the last few years. There is still some variation between hospitals in the use of laparoscopy, but most hospitals are well within the optimal target level.

Rectal cancer

The quality indicators for rectal cancer show that eight out of nine indicators reach the target for optimal achievement, one indicator show a moderate level of achievement and one indicator show a low level of achievement. The reporting rate for clinical reports is 79.1 % for diagnostic work-up and 90.0 % for surgery reports. Estimated relative survival five years after surgery for stage I-III rectal cancer is 89.0 %, and for all stages combined, the 5-year relative survival is 73.5 % (irrespective of surgery and or other treatment). The proportion of patients that do not develop metastasis is 80.5 %. The proportion of patients receiving radiation treatment before surgery is 36.3 %. The proportion of patients with rectal cancer receiving laparoscopy is 83.9 %.